Maravai LifeSciences Holdings Inc. Class A Common Stock vs Motorola Solutions Inc — how do they compare? Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $972.90M), while Motorola Solutions Inc trades at $449.41 (market cap $74.31B). The key difference: Motorola Solutions Inc is far larger — about 76.4× Maravai LifeSciences Holdings Inc. Class A Common Stock's market cap, and Motorola Solutions Inc pays a 1.08% dividend while Maravai LifeSciences Holdings Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days and Motorola Solutions Inc for 101 Days on average.
| MRVI | MSI | |
|---|---|---|
Market Cap | $972.90M | $74.31B |
Volume | 4,325,710 | 847,711 |
Sector | Health | Technology |
52-Week High | $9.00 | $491.24 |
52-Week Low | $2.83 | $363.83 |
Typical Hold Time | 0 Days | 101 Days |
Enterprise Value | $1.08B | $83.22B |
Dividend Yield | — | 1.08% |
Signals from Pluang's Aura AI — not financial advice
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
Motorola Solutions (MSI) trades at $451.49, up 1.19% with a neutral technical outlook. The stock shows strong fundamentals with consistent earnings beats, a record $15.6B backlog (Zacks, 2026-09-28), and robust profitability (17.44% net margin). Recent acquisitions like D-Fend Solutions expand its security footprint, while a $2B share repurchase boost signals confidence. Valuation ratios remain elevated with P/E at 35.38.
Outlook is positive driven by contract wins and AI integration, but high valuation and significant investing cash outflows ($-5.16B in 2025) pose risks. Analyst consensus is bullish (70.59% Buy) with a $525.86 price target, implying 16% upside. Key risks include execution of acquisitions and debt levels (debt-to-asset 47.29% in 2025).
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →Motorola Solutions, Inc. is a data communications and telecommunications equipment provider. The Company develops data capture, wireless, infrastructure, bar code scanning, two-way radios, and wireless broadband networks. Motorola also produces public safety and government products, voice and data communications products and systems, and wireless LAN securities.
Read more on MSI →